AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29457221 — intervention group
Group type: EXPERIMENTAL
Intervention: A alleles of SNP rs324015
Number of subjects: 262
Study 29457221 — intervention group
Group type: EXPERIMENTAL
Intervention: A alleles of SNP rs1059513
Number of subjects: 262
Study 29457221 — intervention group
Group type: EXPERIMENTAL
Intervention: A alleles of both SNPs
Number of subjects: 262
Study 27669095 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus weekly exercise contracting (MI + EC)
Number of subjects: 70
Study 27669095 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and weekly contingency management for exercise (MI + CM)
Number of subjects: 70
Study 27669095 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (MI + EC and MI + CM)
Number of subjects: 70
Study 24450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) training for providers including a 1-day workshop and four 30-minute feedback and coaching sessions.
Number of subjects: 878
Study 24450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) training for providers.
Number of subjects: 878
Study 24450612 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional training enhancements, only mandate compliance.
Number of subjects: 878
Study 22624993 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cream
Number of subjects: 25
Study 22624993 — intervention group
Group type: COMPARATOR
Intervention: Cream base
Number of subjects: 25
Study 22624993 — intervention group
Group type: COMPARATOR
Intervention: Barrier cream
Number of subjects: 25
Study 20530013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg)
Number of subjects: 18
Study 20530013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole dihydrochloride (0.5 mg)
Number of subjects: 18
Study 20530013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18029233 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (information and verbal instruction to exercise by a physiotherapist or physician)
Number of subjects: 314
Study 18029233 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 314
Study 16841679 — intervention group
Group type: EXPERIMENTAL
Intervention: Neiyi pill (NP)
Number of subjects: 58
Study 16841679 — intervention group
Group type: EXPERIMENTAL
Intervention: Neiyi pill (NP) and Neiyi enema (NE)
Number of subjects: 58
Study 16841679 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 58
Study 14520726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (Pulmozyme) treatment
Number of subjects: 13684
Study 14520726 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 13684
Study 10983905 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet (E&D)
Number of subjects: 24
Study 10983905 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (E)
Number of subjects: 24
Study 10983905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 8993958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg/day
Number of subjects: 11
Study 8993958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1350513 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide (1,200 mg/day)
Number of subjects: 7
Study 1350513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3855724 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (3.5 mg/kg) with sodium sulfate (13.25 mg/kg)
Number of subjects: 24
Study 3855724 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (3.5 mg/kg) alone
Number of subjects: 24
Study 3855724 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa with sodium sulfate
Number of subjects: 24
Study 31161447 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gastric bypass
Number of subjects: 343
Study 31161447 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastric bypass
Number of subjects: 343
Study 29737100 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate tablets under fasting conditions
Number of subjects: 24
Study 29737100 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate tablets under high-fat diet conditions
Number of subjects: 24
Study 29737100 — intervention group
Group type: COMPARATOR
Intervention: Two preparations of tenofovir tablets
Number of subjects: 24
Study 27919481 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-Fampridine
Number of subjects: 0
Study 27919481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25226943 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing exercises performed for twenty‐five times a set, four sets a day, 3 days a week, for 8 weeks using dependent load deviation type rowing machines.
Number of subjects: 24
Study 25226943 — intervention group
Group type: COMPARATOR
Intervention: Rowing exercises using previously used water load method.
Number of subjects: 24
Study 22341736 — intervention group
Group type: COMPARATOR
Intervention: PROMUS Element
Number of subjects: 291
Study 22341736 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY
Number of subjects: 291
Study 22341736 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNERGY half dose
Number of subjects: 291
Study 20337074 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain‐fused‐to nickel‐chromium (Ni‐Cr) crown
Number of subjects: 50
Study 20337074 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain‐fused‐to nickel‐chromium‐titanium (Ni‐Cr‐Ti) crown
Number of subjects: 50
Study 17347035 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Reaction Assessment (CRA) questionnaire
Number of subjects: 357
Study 16338260 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily for 8 weeks
Number of subjects: 14
Study 16338260 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 14
Study 12223254 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 182
Study 12223254 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 182
Study 9805725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised questionnaire administered to pregnant women
Number of subjects: 1600
Study 9805725 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions and in-depth interviews with women
Number of subjects: 1600
Study 7662241 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (1 g/kg/day)
Number of subjects: 12
Study 7662241 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric substitute (sucrose, 1.75 g/kg/day)
Number of subjects: 12
Study 7662241 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12
Study 2756307 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine solution (2%)
Number of subjects: 90
Study 2756307 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium suspension (1.5%)
Number of subjects: 90
Study 2756307 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin emulsion (25%)
Number of subjects: 90
Study 767367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 21
Study 767367 — intervention group
Group type: COMPARATOR
Intervention: Periodontal dressing
Number of subjects: 21
Study 31812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil warming executed by infrared heater from 2011 to 2015
Number of subjects: 0
Study 31812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil warming
Number of subjects: 0
Study 31812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous soil warming
Number of subjects: 0
Study 31812424 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbe-mediated attenuation of Rs
Number of subjects: 0
Study 31586218 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle perforator flap reduction mammoplasty using handheld Doppler and colored duplex scan for perforator detection.
Number of subjects: 105
Study 28175941 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare/PS
Number of subjects: 126
Study 28175941 — intervention group
Group type: COMPARATOR
Intervention: Protocol-driven weaning (Control)
Number of subjects: 126
Study 25758270 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide-eluting stent (AES)
Number of subjects: 212
Study 25758270 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 212
Study 22565655 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme aimed at improving handgrip (HS) and pinch strengths (PS) as well as motor coordination of the hand, 20 sessions, twice a week, at-home exercises
Number of subjects: 20
Study 22565655 — intervention group
Group type: COMPARATOR
Intervention: No treatment for hands (control)
Number of subjects: 20
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with no load
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair ascent with no load
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair descent with no load
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a front load (13.6 kg)
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair ascent with a front load (13.6 kg)
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair descent with a front load (13.6 kg)
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a backpack load (13.6 kg)
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair ascent with a backpack load (13.6 kg)
Number of subjects: 17
Study 21733426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair descent with a backpack load (13.6 kg)
Number of subjects: 17
Study 19200163 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-induced platelet aggregation (FIPA) measurement using stainless steel as an agonist
Number of subjects: 111
Study 19200163 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-induced platelet aggregation (FIPA) measurement
Number of subjects: 111
Study 17060309 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention aimed at expanding cultural awareness, sensitivity, and competence.
Number of subjects: 0
Study 17060309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 15589004 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg/day
Number of subjects: 30
Study 15589004 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 4 mg/day
Number of subjects: 30
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakolime(TM) (1% sevoflurane, 2 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Drägersorb(TM) (1% sevoflurane, 2 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisorb(TM) (1% sevoflurane, 2 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsorb(TM) (1% sevoflurane, 2 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakolime(TM) (2% sevoflurane, 1 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Drägersorb(TM) (2% sevoflurane, 1 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisorb(TM) (2% sevoflurane, 1 L/min fresh gas flow)
Number of subjects: 4
Study 10866916 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsorb(TM) (2% sevoflurane, 1 L/min fresh gas flow)
Number of subjects: 4
Study 9399748 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) strategy
Number of subjects: 0
Study 9399748 — intervention group
Group type: COMPARATOR
Intervention: High-dose histamine-2 receptor antagonist (H2RA) strategy
Number of subjects: 0
Study 9399748 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose histamine-2 receptor antagonist (H2RA) strategy
Number of subjects: 0
Study 1287616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 375 mg twice daily
Number of subjects: 1024
Study 1287616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 500 mg twice daily
Number of subjects: 1024
Study 1287616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 750 mg twice daily
Number of subjects: 1024
Study 1287616 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily
Number of subjects: 1024
Study 2992839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg and 4 mg)
Number of subjects: 17
Study 2992839 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocromil (4 mg)
Number of subjects: 17
Study 2992839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3373022 — intervention group
Group type: EXPERIMENTAL
Intervention: gp70-2
Number of subjects: 40
Study 3373022 — intervention group
Group type: EXPERIMENTAL
Intervention: dp72
Number of subjects: 40
Study 30833367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) plus lifestyle counseling
Number of subjects: 139
Study 29231587 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingou diaoyu needling technique combined with Bobath therapy
Number of subjects: 60
Study 29231587 — intervention group
Group type: COMPARATOR
Intervention: Bobath therapy
Number of subjects: 60
Study 25208859 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gray SRT
Number of subjects: 230
Study 25208859 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gray SRT
Number of subjects: 230
Study 25208859 — intervention group
Group type: COMPARATOR
Intervention: Sham SRT
Number of subjects: 230
Study 23263355 — intervention group
Group type: EXPERIMENTAL
Intervention: idebenone (Catena; 900 mg/d)
Number of subjects: 39
Study 23263355 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 21664864 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally-paced training at preferred movement frequency
Number of subjects: 12
Study 21664864 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally-paced training at more demanding frequency
Number of subjects: 12
Study 21664864 — intervention group
Group type: COMPARATOR
Intervention: Self-paced training
Number of subjects: 12
Study 19463354 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZoMaxx)
Number of subjects: 401
Study 19463354 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (Taxus)
Number of subjects: 401
Study 17070426 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline echocardiography (echo group)
Number of subjects: 177
Study 17070426 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist therapy in echo group
Number of subjects: 177
Study 17070426 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II receptor antagonist therapy in control group
Number of subjects: 177
Study 17070426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean left ventricular mass index after 6 months
Number of subjects: 177
Study 17070426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean diastolic 24-h ambulatory BP monitoring after 6 months
Number of subjects: 177
Study 17070426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic and diastolic office BP after 6 months
Number of subjects: 177
Study 12668364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-80 mg twice daily)
Number of subjects: 210
Study 12668364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 10743446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (bolus 0.1 mg kg‐1 over 10 min followed by infusion of 7 micrograms kg‐1 min‐1)
Number of subjects: 12
Study 10743446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg kg‐1)
Number of subjects: 12
Study 10743446 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 8941101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress tasks (simulated public speaking and the Stroop Color-Word Test)
Number of subjects: 29
Study 8941101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress tasks
Number of subjects: 29
Study 1383302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 30
Study 1383302 — intervention group
Group type: COMPARATOR
Intervention: Attention and information
Number of subjects: 30
Study 1383302 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 3888337 — intervention group
Group type: COMPARATOR
Intervention: Simple closure (Group I, 33 patients)
Number of subjects: 78
Study 3888337 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive surgery (Group II, 32 patients)
Number of subjects: 78
Study 30176216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent heat acclimation (INT) - 8 sessions over 15 days
Number of subjects: 16
Study 30176216 — intervention group
Group type: COMPARATOR
Intervention: Continuous heat acclimation (CON) - 8 sessions over 8 days
Number of subjects: 16
Study 30176216 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 16
Study 30176216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both INT and CON
Number of subjects: 16
Study 29319935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A (50 mg)
Number of subjects: 16
Study 29319935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet B (50 mg)
Number of subjects: 16
Study 29319935 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (50 mg)
Number of subjects: 16
Study 29319935 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations (Tablet A, Tablet B, Oral Solution)
Number of subjects: 16
Study 27875528 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine‐pyrimethamine (SP) plus amodiaquine (AQ)
Number of subjects: 780000
Study 27875528 — intervention group
Group type: COMPARATOR
Intervention: Control (no SMC)
Number of subjects: 780000
Study 24894963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg twice daily
Number of subjects: 84
Study 22403324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine/Artesunate (PA) for 3 days
Number of subjects: 34
Study 22403324 — intervention group
Group type: COMPARATOR
Intervention: Pyronaridine/Artesunate (PA) with Ritonavir (100 mg twice daily for 17 days, PA administered on Days 8-10)
Number of subjects: 34
Study 20353110 — intervention group
Group type: COMPARATOR
Intervention: Group A: Routine treatments in western medicine including gastrointestinal decompression, parenteral nutrition, anti-infection, supportive therapy.
Number of subjects: 240
Study 20353110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Electroacupuncture in Zusanli (ST 36), Shangjuxu (ST 37) in addition to Group A treatments.
Number of subjects: 240
Study 20353110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Acupoint injection with Neostigmine in Dachangshu (BL 25), Zusanli (ST 36) in addition to Group A treatments.
Number of subjects: 240
Study 20353110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: All treatments from Groups A, B, and C.
Number of subjects: 240
Study 18279216 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-S (metered-dose inhaler with spacer)
Number of subjects: 21
Study 18279216 — intervention group
Group type: COMPARATOR
Intervention: DPI (dry powder inhaler)
Number of subjects: 21
Study 18279216 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-S
Number of subjects: 21
Study 18279216 — intervention group
Group type: COMPARATOR
Intervention: DPI
Number of subjects: 21
Study 16169341 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (10 minutes bolus with 12 microg/kg followed by 0.1 microg/kg per minute for 24 hours)
Number of subjects: 26
Study 16169341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12110497 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) plus interleukin-2 (IL-2) with or without cisplatin
Number of subjects: 131
Study 12110497 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFNalpha) plus interleukin-2 (IL-2) with cisplatin
Number of subjects: 131
Study 10220012 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐141C Del allele in schizophrenia patients (n = 50)
Number of subjects: 101
Study 10220012 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 51)
Number of subjects: 101
Study 8556848 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to color or shape (selective attention)
Number of subjects: 0
Study 8556848 — intervention group
Group type: EXPERIMENTAL
Intervention: Different dimensions judged for two stimuli (color and shape)
Number of subjects: 0
Study 2228819 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 47
Study 2228819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 47
Study 156408 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline incision
Number of subjects: 49
Study 156408 — intervention group
Group type: COMPARATOR
Intervention: Subcostal incision
Number of subjects: 49
Study 28283823 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried blueberry (24 g/day, equivalent to 1 cup of fresh blueberries) for 90 days
Number of subjects: 37
Study 28283823 — intervention group
Group type: COMPARATOR
Intervention: Blueberry placebo
Number of subjects: 37
Study 26968101 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean CKD-EPI equation
Number of subjects: 960
Study 26968101 — intervention group
Group type: COMPARATOR
Intervention: Original CKD-EPI equation
Number of subjects: 960
Study 24793893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 3 g
Number of subjects: 101
Study 24793893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 101